- email:registrations@informa-ls.com
- phone:+44(0)20 7017 7481
 |
Non-Antibody Protein Production 2012
24 - 25 May 2012, Diplomat Hotel, Prague, Czech Republic
|
Informa's 2nd annual Non-Antibody Protein Production Conference
Europe's only event dedicated to the production, analytical and formulation studies of Non-Antibody proteins
Informa Life Sciences are delighted to bring to you our 2nd annual Conference on the Production of Non-Antibody Proteins. 2012 sees an expanded agenda with 2 new streams focusing on upstream, downstream, analytical developments of non-antibody proteins.
Where do non-antibodies fit in an antibody world? Discover new technologies being developed and and what platforms are being exploited for the recovery and purification of these unique proteins.
Importantly, this event will also provide a platform to look specifically at what it means to develop products using microbial expression systems and the associated downstream, recovery, formulation and QbD issues encountered.
With top level speakers from both large and small Biotech companies, you will gain a complete insight into how experts are tackling these issues head-on.
Highlights of Informa's Non-Antibody Protein Production 2012 agenda
- Critical, first-hand advice on the latest advances in bacterial expression systems with an update on the industry developments from Genentech, Pieris-AG and SuppreMol
- Discover the latest microbial modifications being employed by Glycofi, Phage Pharmaceuticals and University of Sheffield in creating the next generation of microbial expression systems
-
Effectively establish purification platforms for your non mAb programs with the latest case studies from UCB Celltech, Abbott , Ohio State University, Synthon and Bayer Pharmaceuticals
- Perform successful characterizations studies with the latest case studies from Merck Serono, GlaxoSmithKlein and Novo Nordisk
- Overcome unique formulation challenges presented by Non mAb proteins with revelations from Immunocore and the University of Bath
Your expert speaker panel includes
Hear from the leaders in the non-antibody community
Your expert speaker panel includes
Dr David Wood
Dept of Chemical and Biomolecular Engineering
Ohio State University, USA
|
Dr William Gillette
Sr. Scientist
SAIC-Frederick, Inc, USA
|
Dr Corne Stroop
Senior Research Scientist, Quality
Merck Sharp Dhome, The Netherlands
|
Dr Felix Oehme
Senior Scientist
BayerSchering Pharma, Germany
|
PLUS:
Dr Laenen Lada, Managing Principle Scientist, Genzyme, Belgium
Dorothea E. Reilly, Early Stage Cell Culture, Genentech, USA
Dr Bruno Antonsson, Principal Scientist, Head Protein Biochemistry, Merck Serono, Switzerland
Dr Christian Rischel, Senior Scientist, Protein Structure and Biophysics, Novo Nordisk, Denmark
Dr Troy McSherry, Principal Scientist, Diagnostics Devision, Abbott Laboratories, USA
Dr David Bramhill, Director, RCTech, USA
Dr Michel Plisnier, Head of Structural Biochemsitry Platform, GlaxoSmithKlein, Belgium
Professor Antonio Villaverde, Head of Mircobiology, Universitat Autònoma de Barcelona, Spain
Dr Jamie Oliver, President and CEO, Phage Pharmaceuticals, USA
Dr Morten Nørholm, Associate Professor, Novo Nordisk Foundation Center, Denmark
Dr Michel Eppink, Head of Downstream Processing, Synthon, Netherlands
Dr Mark Ellis, Senior Scientist, UCB, UK
Dr Eef Dirkson, Senior Scientist, MSD, Netherlands
Dr Richard Francis, CEO and President, Francis Biopharma, UK
Gavin Wild, Principal Scientist, UCB, UK
Sponsors
Media Partners
New for 2012!
- Expanded agenda with 2 new streams focusing on upstream, downstream, analytical and formulation developments for non-antibody proteins
- 32+new industry speakers
- 2 expert lead interactive panels on expression systems and purification platforms
- Focused sessions on the optimisation of microbial systems
- 4 new workshops on the key challenges facing non-antibody development
4 dedicated workshops to non-antibody protein production
PRE-CONFERENCE WORKSHOP X:
Wednesday 24 May 2012
Comparison of Expression Systems and Successful Scale Up Strategies
Led by:
Dr. Ian Hodgson, Senior Scientist, Fujifilm Diosynth Biotechnologies, UK
-----------------------------------
PRE-CONFERENCE WORKSHOP Y:
Wednesday 24 May 2012
Establish a Successful Purification Platform
Led by:
Dr William Gillette, Sr. Scientist, SAIC-Frederick, Inc, USA
Dr David Wood, Dept of Chemical and Biomolecular engineering, Ohio State University, USA
-----------------------------------
EVENING SEMINAR A:
Thursday 24 May 2012
Optimise the Development of Biosimilars
Led by:
Dr Francois Lawny, VP Biotechnology, Triskel Integrated Services, Switzerland
-----------------------------------
EVENING SEMINAR B:
Thursday 24 May 2012
Developability Studies for Non-Antibodies
Led by:
Andreas Hohlbaum, VP Strategic Res. & Project Management, Pieris Ag, Germany
Martinus Capelle, Senior Scientist, Therapeomic Inc, Switzerland
Feeds | Like | Share    |
With members from the Non-Antibody Protein Production group, join this growing community with experts from around the world and discuss the latest challenges in this area as well as discovering the latest methods for overcoming them. Join us in Linkedin!
Sponsors
Poll
Do you think we are due a resurgence of interest in the development of non-antibody proteins?
Please select an answer
